Centessa Pharmaceuticals Plc (CNTA) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Centessa Pharmaceuticals Plc  (NASDAQ: CNTA)


Centessa Pharmaceuticals Plc's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Centessa Pharmaceuticals Plc's ROA in the first quarter of 2026?
Centessa Pharmaceuticals Plc recorded a cumulative net loss of $-251 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -44.17%.

However, within the Healthcare sector 523 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 3850, from total ROA ranking in the fourth quarter of 2025 at 4396.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Total Assets Change 21.58 % 27.28 % -21.65 % 36.55 % 82.38 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -251 -198 -243 -230 -224
Return On Assets (TTM) -44.17 % -36.65 % -48.34 % -43.22 % -44.76 %
CNTA's Total Ranking # 3850 # 4396 # 4000 # 3976 # 4049
Total Assets (TTM) in million 642 687 448 492 528
Seq. Total Assets Change -6.65 % 53.36 % -8.91 % -6.77 % -2.28 %
Seq. Net Income Change - - - - -

CNTA's 5 Years Annual ROA >> Back to CNTA Management Effectiveness >> Compare CNTA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 216
Sector # 524
Overall # 3816

Return On Assets Statistics
High Average Low
-8.83 %
-36.84 %
-49.28 %
(Mar 31 2022)   (Dec 31 2024)



  News about Centessa Pharmaceuticals Plc Return on Assets ROA

Centessa Pharmaceuticals Reveals Positive Interim Phase 1 Data for ORX750, Heralding a New Hope for Sleep Disorder Tr...

Centessa Pharmaceuticals Announces Promising Interim Phase 1 Data for ORX750: A Potential Breakthrough in Treating Sleep Disorders BOSTON and LONDON September 10, 2024 Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, has unveiled encouraging interim data from their ongoing Phase 1 clinical trial for ORX750, a novel and highly potent orexin receptor 2 (OX2R) agonist. The study, conducted with acutely sleep-deprived healthy volunteers, showed that ORX750 could significantly improve wakefulness, paving the way for future treatments for sleep disorders like narcolepsy and idiopathic hypersomnia.Set against the backdrop of an increasing need for effective sleep disorder interventions, the results demonstrated that ORX750 markedly enhances mean sleep latency, a measure of the time it takes for a person to fall asleep. The Maintenance of Wakefulness Test (MWT) results indicated that both 1.0 mg and 2.5 mg doses of ORX750 led to clinically meaningful and statistically significant improvements in mean sleep latency when compared to a placebo. Notably, the 2.5 mg dose achieved what the researchers described as ormative wakefulness, posting a mean sleep latency of 32 minutes as measured by the MWT.



Financial Statements
Centessa Pharmaceuticals Plc's Assets $ 642 million CNTA's Balance sheet
Centessa Pharmaceuticals Plc's Income $ -79 million Quarterly CNTA's Income Statement
CNTA's Income by Division See CNTA's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 27.28 % 49.99 % -18.95 % -29.43 % -
Total Assets in million 687 540 360 444 630
Y / Y Net Income Change - - - - -
Net Income in million -198 -236 -151 -216 -11
Annual Return On Assets -28.73 % -43.65 % -41.95 % -48.66 % -1.69 %

CNTA's 5 Years Annual ROA >> Back to CNTA Management Effectiveness >> Compare CNTA ROA to its Competitors



More Return On Assets Ratios
CNTA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CNTA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CNTA's Competitors
Subscribers only: Roa for Centessa Pharmaceuticals Plc's Suppliers
Subscribers only: Return On Assets for CNTA's Customers

You may also want to know
CNTA's Roi CNTA's Inventory Turnover Ratio CNTA's Growth Rates CNTA's Dividend Comparisons
CNTA's Profitability Ratios CNTA's Asset Turnover Ratio CNTA's Dividend Growth
CNTA's Roe CNTA's Valuation Ratios CNTA's Financial Strength Ratios CNTA's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA

Date modified: 2026-09-26T07:40:22+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.